Clinical Trial Update: Concurrent Dabrafenib + Trametinib With Sterotactic Radiation in BRAF Mutation-Positive Malignant Melanoma and Brain Metastases [Phase 2]

View source ↗

Summary

Phase 2 trial investigating concurrent dabrafenib and trametinib with stereotactic radiotherapy for BRAF mutation-positive melanoma with brain metastases; study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Melanoma

Drugs mentioned

• Dabrafenib (Dabrafenib)
• Trametinib (trametinib)

Snippet

Sponsor: Canadian Cancer Trials Group | Conditions: Melanoma, Brain Metastases | Phase 2 | Status: TERMINATED | Results posted: 2021-08-17